Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 8/20 | 0.46 |
| ▸ | FAAH | O00519 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.33 |
| ▸ | CASP2 | P42575 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL71315 | 1.00 | GLP1R (0.46) | GLP1RFAAHMEN1KMT2ATSHR | |
| SCHEMBL14683575 | 0.97 | FAAH (0.43) | GLP1RFAAHMEN1KMT2ATSHR | |
| SCHEMBL13805652 | 0.92 | GLP1R (0.49) | GLP1RFAAHMEN1KMT2ATSHR | |
| SCHEMBL71906 | 0.92 | MEN1 (0.45) | GLP1RFAAHMEN1KMT2ATSHR | |
| SCHEMBL14683527 | 0.92 | GLP1R (0.44) | GLP1RFAAHMEN1KMT2ATSHR | |
| SCHEMBL14683467 | 0.92 | GLP1R (0.44) | GLP1RFAAHMEN1KMT2ATSHR | |
| SCHEMBL13805654 | 0.91 | GLP1R (0.53) | GLP1RFAAHMEN1KMT2ATSHR | |
| SCHEMBL12118613 | 0.91 | GLP1R (0.42) | GLP1RFAAHMEN1KMT2ATSHR | |
| SCHEMBL13805653 | 0.90 | GLP1R (0.57) | GLP1RFAAHEPHX2CASP2 | |
| SCHEMBL14683460 | 0.90 | GLP1R (0.41) | GLP1RFAAHMEN1KMT2ATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9012398-B2 | Acylated exendin-4 compounds | NOVO NORDISK A/S (DK) | 2015-04-21 | — | — | US | disclosed |
| US-20120283170-A1 | Acylated Exendin-4 Compounds | NOVO NORDISK A/S (DK) | 2012-11-08 | — | — | US | disclosed |
| US-8129343-B2 | Acylated GLP-1 compounds | NOVO NORDISK A/S (DK) | 2012-03-06 | — | — | US | disclosed |
| US-20090156478-A1 | Acylated GLP-1 Compounds | NOVO NORDISK A/S (DK) | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156478-A1 | Acylated GLP-1 Compounds | GLP1R, GIPR, GCGR | GLP1R 1/4885FAAH 193/4885MEN1 922/4885 |
| US-20120283170-A1 | Acylated Exendin-4 Compounds | GLP1R, VIP, IAPP | GLP1R 1/4885FAAH 163/4885MEN1 602/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.